Liu Shuang, Tang Shaohua, Dong Hong, Huang Xiaohan
Department of Ophthalmology, Beijing Jishuitan Hospital, Beijing 100035, P.R. China.
Exp Ther Med. 2020 Aug;20(2):1815-1821. doi: 10.3892/etm.2020.8838. Epub 2020 Jun 4.
Meibomian gland dysfunction (MGD) is frequently encountered by eye care practitioners. It is characterised by obstruction of the Meibomian glands and/or alterations in the consistency of glandular secretions. At present, no definitive treatment exists for this condition. The present meta-analysis was performed to assess the efficacy of intense pulsed light (IPL) therapy in the management of MGD. Databases including EMBASE, PubMed, Cochrane Central, MEDLINE and Google Scholar were systematically searched to identify clinical trials that assessed the efficacy of IPL in the treatment of MGD. Outcome measures were described as the standardized mean difference (SMD). The fixed- or random-effects model was selected for analysis based on the Cochrane I values representing heterogeneity. Publication bias was visually inspected using Begg's funnel plot. Data were synthesized from four randomized controlled trials (RCTs) comprising 122 subjects in the IPL group and 120 subjects in the control group. Pooled analysis indicated no statistically significant difference in the Standard Patient Evaluation of Eye Dryness (SPEED) scores between the two groups [SMD -0.16 (95% CI, -0.41 to 0.10)] but a significant increase in Non-Invasive Tear Break-Up Time (NIBUT) scores in the IPL group (SMD, 0.90; 95% CI, 0.40-1.40). To conclude, the results of the present study did not provide any conclusive evidence for the efficacy of IPL therapy in the management of MGD. The analysis indicated that IPL therapy may result in an improvement of objective NIBUT scores but has no effect on subjective SPEED scores. Given the limited number of studies performed to date, there is a requirement for more well-designed prospective RCTs with a larger sample size to provide further evidence on the efficacy of IPL therapy.
睑板腺功能障碍(MGD)是眼科护理从业者经常遇到的问题。其特征是睑板腺阻塞和/或腺分泌物稠度改变。目前,针对这种情况尚无确切的治疗方法。进行本次荟萃分析是为了评估强脉冲光(IPL)疗法在治疗MGD中的疗效。系统检索了包括EMBASE、PubMed、Cochrane中心、MEDLINE和谷歌学术在内的数据库,以确定评估IPL治疗MGD疗效的临床试验。结果指标用标准化均数差(SMD)表示。根据代表异质性的Cochrane I值选择固定效应模型或随机效应模型进行分析。使用Begg漏斗图直观检查发表偏倚。数据来自四项随机对照试验(RCT),IPL组有122名受试者,对照组有120名受试者。汇总分析表明,两组之间在干眼标准患者评估(SPEED)评分上无统计学显著差异[SMD -0.16(95%CI,-0.41至0.10)],但IPL组的非侵入性泪膜破裂时间(NIBUT)评分显著增加(SMD,0.90;95%CI,0.40 - 1.40)。总之,本研究结果未提供任何确凿证据证明IPL疗法在治疗MGD方面的疗效。分析表明,IPL疗法可能会改善客观的NIBUT评分,但对主观的SPEED评分没有影响。鉴于迄今为止进行的研究数量有限,需要更多设计良好、样本量更大的前瞻性RCT,以提供关于IPL疗法疗效的进一步证据。